Ardelyx Stock Forecast, Price & News

-0.05 (-2.74 %)
(As of 08/4/2021 03:01 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume156,577 shs
Average Volume23.45 million shs
Market Capitalization$157.44 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ARDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

Ardelyx logo

About Ardelyx

Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.42 out of 5 stars

Medical Sector

152nd out of 1,309 stocks

Pharmaceutical Preparations Industry

78th out of 646 stocks

Analyst Opinion: 4.3Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

Is Ardelyx a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ardelyx stock.
View analyst ratings for Ardelyx
or view top-rated stocks.

What stocks does MarketBeat like better than Ardelyx?

Wall Street analysts have given Ardelyx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ardelyx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Ardelyx?

Ardelyx saw a increase in short interest in June. As of June 30th, there was short interest totaling 9,140,000 shares, an increase of 20.9% from the June 15th total of 7,560,000 shares. Based on an average daily volume of 2,200,000 shares, the short-interest ratio is presently 4.2 days. Approximately 12.2% of the company's shares are short sold.
View Ardelyx's Short Interest

When is Ardelyx's next earnings date?

Ardelyx is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Ardelyx

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) announced its quarterly earnings data on Wednesday, May, 5th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by $0.01. The biopharmaceutical company earned $6.58 million during the quarter, compared to analysts' expectations of $1.10 million. Ardelyx had a negative trailing twelve-month return on equity of 78.63% and a negative net margin of 812.17%.
View Ardelyx's earnings history

How has Ardelyx's stock been impacted by COVID-19 (Coronavirus)?

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARDX stock has decreased by 73.2% and is now trading at $1.6050.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ARDX?

8 brokerages have issued 1-year target prices for Ardelyx's stock. Their forecasts range from $2.00 to $15.00. On average, they anticipate Ardelyx's stock price to reach $7.46 in the next year. This suggests a possible upside of 365.0% from the stock's current price.
View analysts' price targets for Ardelyx
or view top-rated stocks among Wall Street analysts.

Who are Ardelyx's key executives?

Ardelyx's management team includes the following people:
  • Mr. Michael G. Raab, Pres, CEO & Director (Age 56, Pay $947.66k) (LinkedIn Profile)
  • Mr. Justin A. Renz CPA, MST, M.S.T., MBA, CFO & Chief Accounting Officer (Age 49, Pay $394.74k)
  • Ms. Susan Rodriguez, Chief Commercial Officer (Age 57, Pay $588.96k)
  • Mr. Jeffrey W. Jacobs, Chief Scientific Officer (Age 58) (LinkedIn Profile)
  • Ms. Elizabeth A. Grammer, Chief Legal & Admin. Officer and Sec. (Age 57)
  • Ms. Kimia Keshtbod, Mang. of Corp. Communications & Investor Relations
  • Mr. David P. Rosenbaum, Chief Devel. Officer (Age 60) (LinkedIn Profile)
  • Mr. Robert C. Blanks, Chief Regulatory Affairs & Quality Assurance Officer (Age 61)
  • Ms. Karen Harrigan, Sr. Director Market Devel.
  • Dan Pavicich, Sr. Director of Market Devel.

Who are some of Ardelyx's key competitors?

What other stocks do shareholders of Ardelyx own?

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (0.07%), New York State Common Retirement Fund (0.07%), Russell Investments Group Ltd. (0.07%), Eidelman Virant Capital (0.02%), Advisor Group Holdings Inc. (0.01%) and Cutler Group LP (0.00%). Company insiders that own Ardelyx stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Mark Kaufmann, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends for Ardelyx

Which institutional investors are selling Ardelyx stock?

ARDX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd.. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Michael Raab, Robert Blanks, and Susan Rodriguez.
View insider buying and selling activity for Ardelyx
or view top insider-selling stocks.

Which institutional investors are buying Ardelyx stock?

ARDX stock was bought by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Eidelman Virant Capital, Advisor Group Holdings Inc., Alliancebernstein L.P., and Cutler Group LP.
View insider buying and selling activity for Ardelyx
or or view top insider-buying stocks.

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $1.61.

How much money does Ardelyx make?

Ardelyx has a market capitalization of $158.43 million and generates $7.57 million in revenue each year. The biopharmaceutical company earns $-94,310,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.

How many employees does Ardelyx have?

Ardelyx employs 129 workers across the globe.

What is Ardelyx's official website?

The official website for Ardelyx is

Where are Ardelyx's headquarters?

Ardelyx is headquartered at 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.